{"entity":{"id":"nct05879055","kind":"trial","name":"A Study of PM8002 in Combination With Chemotherapy in Patients With NEN","aka":[],"tldr":"A phase 2 trial of PM8002 in neuroendocrine tumours, run by Biotheus Inc., active and no longer recruiting.","summary":"A Study of PM8002 in Combination With Chemotherapy in Patients With NEN is a phase 2 interventional study registered as NCT05879055 by Biotheus Inc., with 31 participants enrolled, started 2023-05-17 and due to reach its primary completion in 2027-01-01. Interventions recorded: PM8002 and FOLFIRI.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05879055","url":"https://clinicaltrials.gov/study/NCT05879055"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["neuroendocrine"],"sections":[],"technologies":[],"targets":[],"drugs":["pm8002"],"companies":["biontech"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05879055","phase":"2","setting":"A Phase II Study to Evaluate the Efficacy, Safety and Pharmacokinetics of PM8002 Injection in Combination With Chemotherapy as Second Line Therapy in Unresectable Neuroendocrine Neoplasm","sponsor":"Biotheus Inc.","enrolled":31,"outcomes":[]},"route":"/trials/nct05879055/","neighbours":{"cancer":[{"id":"neuroendocrine","kind":"cancer","name":"Neuroendocrine tumours","route":"/cancers/neuroendocrine/"}],"drug":[{"id":"pm8002","kind":"drug","name":"PM8002","route":"/drugs/pm8002/"}],"company":[{"id":"biontech","kind":"company","name":"BioNTech","route":"/companies/biontech/"}]}}